Biocept Stock Price and Value Analysis

Should you buy Biocept stock? (NasdaqCM:BIOC). Let's see how it does in our automated value investing analysis system.

  • This company has stable growth.
  • This company is less known than others.
  • This company is not making money.
  • This stock looks overpriced.
  • This company pays no dividend.

Inside the BIOC Numbers

BIOC Price
(Biocept stock price per share)
[?] PE Ratio versus Sector 67% lower than other Healthcare stocks
[?] PE Ratio versus Industry 0% lower than other Diagnostics & Research stocks
[?] Cash Yield -62.67%
[?] Free Cash Flow Jitter 16%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 311,477 shares shorted. With 16,844,263 shares available for purchase and an average trading volume over the past 10 trading days of 107,320, it would take at least 2.902 days for all of the short holders to cover their shorts.

Is Biocept Stock on Sale?

Based on our analysis, we believe that you should not buy Biocept right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy BIOC Stock?

Does Biocept have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.